LGALS1 and melanoma: An ancillary mechanism that supports the rationale of this triplet is suggested by the immune response elicited by anti-CTLA4 + anti-VEGF doublet in melanoma patients: the increase of cancer-specific targets IgG, such as galectin-1, seen in melanoma patients couldbe translated to the aHCC setting as well [43].